ATE546524T1 - Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür - Google Patents

Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür

Info

Publication number
ATE546524T1
ATE546524T1 AT08719320T AT08719320T ATE546524T1 AT E546524 T1 ATE546524 T1 AT E546524T1 AT 08719320 T AT08719320 T AT 08719320T AT 08719320 T AT08719320 T AT 08719320T AT E546524 T1 ATE546524 T1 AT E546524T1
Authority
AT
Austria
Prior art keywords
libraries
scfv antibodies
producing active
active scfv
producing
Prior art date
Application number
AT08719320T
Other languages
English (en)
Inventor
Pierre Martineau
Etienne Weiss
Original Assignee
Inst Nat Sante Rech Med
Univ Pasteur
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Pasteur, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE546524T1 publication Critical patent/ATE546524T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08719320T 2007-03-15 2008-03-17 Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür ATE546524T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89494707P 2007-03-15 2007-03-15
PCT/IB2008/000628 WO2008110914A2 (en) 2007-03-15 2008-03-17 Methods for producing active scfv antibodies and libraries therefor

Publications (1)

Publication Number Publication Date
ATE546524T1 true ATE546524T1 (de) 2012-03-15

Family

ID=39760160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08719320T ATE546524T1 (de) 2007-03-15 2008-03-17 Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür

Country Status (7)

Country Link
US (2) US20090143247A1 (de)
EP (1) EP2134841B9 (de)
JP (1) JP5385796B2 (de)
AT (1) ATE546524T1 (de)
CA (1) CA2681170C (de)
ES (1) ES2384006T3 (de)
WO (1) WO2008110914A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010249470B2 (en) * 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
EP2548030B1 (de) * 2010-03-18 2015-05-27 Cornell University Engineering korrekt gefalteter antikörper mit membraninterner anzeige von twin-arginin-translokations-zwischenprodukten
EP2558587A4 (de) * 2010-04-12 2015-05-06 Sorrento Therapeutics Inc Verfahren zur anzeige von antikörpern
EP2752487A1 (de) 2013-01-03 2014-07-09 Sanofi Intrazelluläres Phänotypen-Screening
KR101740030B1 (ko) * 2014-03-07 2017-05-29 사회복지법인 삼성생명공익재단 ScFv 항체 라이브러리, 이의 제조방법 및 이를 이용한 ScFv 항체 스크리닝 방법
CA3084315A1 (en) 2017-12-11 2019-06-20 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
JP2025519070A (ja) 2022-05-17 2025-06-24 エンヴェロップ セラピューティクス, インコーポレイテッド 効率的in vivo送達のための組成物および方法
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1999045959A1 (en) * 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US6058338A (en) 1999-02-12 2000-05-02 Qualcomm Incorporated Method and apparatus for efficient GPS assistance in a communication system
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
EP1479694B1 (de) * 1999-12-28 2016-10-26 ESBATech, an Alcon Biomedical Research Unit LLC ScFv Intrakörper mit definierter Struktur ("Framework"), der in einer reduzierenden Umgebung stabil ist
US20040096826A1 (en) 2002-01-30 2004-05-20 Evans Glen A. Methods for creating recombination products between nucleotide sequences
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof

Also Published As

Publication number Publication date
US8841238B2 (en) 2014-09-23
JP2010521447A (ja) 2010-06-24
US20100167957A1 (en) 2010-07-01
JP5385796B2 (ja) 2014-01-08
CA2681170A1 (en) 2008-09-18
ES2384006T3 (es) 2012-06-28
WO2008110914A2 (en) 2008-09-18
EP2134841B1 (de) 2012-02-22
EP2134841B9 (de) 2014-06-11
WO2008110914A3 (en) 2009-02-26
EP2134841A2 (de) 2009-12-23
US20090143247A1 (en) 2009-06-04
CA2681170C (en) 2017-10-31

Similar Documents

Publication Publication Date Title
WO2009112245A9 (en) Antibody against the csf-1 r
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
LTC2567976I2 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
ECSP078026A (es) Anticuerpos anti-cd40 humanizados y sus métodos de uso
PH12013502230A1 (en) Multispecific antibodies
LTC2068874I2 (lt) Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
DE602006013029D1 (de) Anti-egfr-antikörper
ATE469908T1 (de) Verfahren zur herstellung von pimecrolimus
MX350375B (es) Moleculas de union especificas de virus sincitial respiratorio y medios para producirlas.
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
ATE554105T1 (de) Veränderte antikörper
MX347020B (es) Anticuerpo contra el csf-1r.
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
DK201100184U1 (da) Method for immunizing an avian species
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
WO2008027236A3 (en) Multispecific antibodies
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
WO2008110914A3 (en) Methods for producing active scfv antibodies and libraries therefor
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
NO20084878L (no) Humanisert C-kit antistoff
ATE543910T1 (de) Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen
CN103562403A8 (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
EP4087862A4 (de) Antitigit-antikörper, multispezifische antikörper, die dieseelben umfassen, und verfahren zur verwendung derselben